Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia,Canada
Free accessResearch articleFirst published online October, 2015
Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia,Canada
Nevirapine 400 mg extended release tablets (nevirapine-XR) are a once-daily alternative to nevirapine 200 mg immediate release tablets (nevirapine-IR). Study objectives were to describe the effectiveness and tolerability of nevirapine-XR in clinical practice and, for patients who switched from once daily 2x200 mg nevirapine-IR to nevirapine-XR, compare virological suppression and plasma nevirapine concentrations during each treatment period.
Methods
HIV-1-infected adults entered the study cohort if they initiated nevirapine-XR in British Columbia (BC) Canada between 1 April 2012 and 30 September 2012 and were followed until 30 September 2013. Demographic and clinical variables were abstracted from the BC Centre for Excellence in HIV/AIDS databases. Patients who switched from once daily nevirapine-IR to nevirapine-XR were monitored for 6 months pre- and post-switch with comparison of virological suppression (McNeamer's test) and median random plasma nevirapine concentrations (Wilcoxon–Mann–Whitney test) in each period.
Results
The 536 nevirapine-XR-treated patients were 96% male, median (IQR) age 49.9 (44.0–56.9) years. Median follow-up was 15.6 (14.7–16.5) months, with 474/536 (88%) maintaining virological suppression. Emergent drug resistance developed in 5/536 (1%), adverse drug reactions in 17/536 (3%) and, although 31/536 (6%) reported ‘whole’ tablets in their stools, this was not associated with adverse outcomes. Among the 305 patients who switched from nevirapine-IR to nevirapine-XR, median (IQR) random plasma nevirapine concentration was higher during nevirapine-IR 5,000 (3,690–6,090) ng/ml than nevirapine-XR 3,930 (3,050–5,150) ng/ml (P<0.001), but there was no difference in virological suppression, 89% and 87% respectively (P=0.414).
Conclusions
This post-marketing study affirms the effectiveness and tolerability of nevirapine-XR as an alternative to nevirapine-IR in adults.
References
1.
Health Canada, Ottawa ON, Canada.Drug Product Database Online Query. (Product name: Viramune, Viramune XR). (Updated 25 February 2013. Accessed 24 December 2013.) Available from http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp.
World Health Organization, Geneva.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. (Updated 30 June 2013. Accessed 24 December 2013.) Available from http://www.who.int/hiv/pub/guidelines/arv2013/download/en/.
4.
BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.Antiretroviral (ARV) treatment of adult HIV infection. (Updated February 2013. Accessed 24 December 2013.) Available from http://cfenet.ubc.ca/therapeutic-guidelines/adult.
5.
Department of Health and Human Services, Rockville, MD, USA.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 12 February 2013. Accessed 24 December 2013.) Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
6.
Guidelines version 7.0European AIDS Clinical Society, Brussels, Belgium. (Updated October 2013. Accessed 24 December 2013.) Available from http://www.eacsociety.org/Guidelines.aspx.
De LazzariE., LeonA., ArnaizJ.A.Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.HIV Med2008; 9: 221–226.
9.
KesselringA.M., WitF.W., SabinC.A.Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.AIDS2009; 23: 1689–1699.
10.
WitF.W., KesselringA.M., GrasL.Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.Clin Infect Dis2008; 46: 933–940.
11.
CalmyA., VallierN., NguyenA.Safety and efficacy of once-daily nevirapine dosing: a multicohort study.Antivir Ther2009; 14: 931–938.
12.
CooperC.L., van HeeswijkR P.Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.HIV Med2007; 8: 1–7.
13.
ReliquetV., AllavenaC., Morineau-Le HoussineP., MounouryO., RaffF.Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients.HIV Clin Trials2010; 11: 110–117.
14.
RachelTherrien. A basic guide to antiretrovirals. 5th ed. Programme national de mentorat sur le VIH/SIDA, Montreal QC, Canada. (Updated April 2008. Accessed 24 Dec 2013.) Available from http://www.hivmedicationguide.com/pdf/GuideARVs2008.pdf.
15.
van LethF., PhanuphakP., RuxrungthamK.Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study.Lancet2004; 363: 1253–1263.
16.
PodzamczerD., OlmoM., SanzJ.Safety of switching nevirapine twice daily to nevirapine once daily in virologically suppressed patients.J Acquir Immune Defic Syndr2009; 50: 390–396.
17.
GatheJ., Andrade-VillanuevaJ., SantiagoS.Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.Antivir Ther2011; 16: 759–769.
18.
ArastehK., WardD., PlettenbergA.Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).HIV Med2012; 13: 236–244.
HarriganP.R., HoggR.S., DongW.W.Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.J Infect Dis2005; 191: 339–347.
LimaV., HarriganR., MontanerJ.S.Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay.J Acquir Immune Defic Syndr2009; 51: 3–6.
27.
de Vries-SluijsT.E., DielemanJ.P., ArtsD.Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.Clin Pharmacokinet2003; 42: 599–605.
28.
VeldkampA.I., WeverlingG.J., LangeJ.M.High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.AIDS2001; 15: 1089–1095.
29.
HigginsN., TsengA., SheehanN.L., la PorteC.J.Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice.Can J Hosp Pharm2009; 62: 500–509.
30.
DuongM., BuissonM., PeytavinG.Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors.Ann Pharmacother2005; 39: 603–609.
31.
KappelhoffB.S., HuitemaA.D., van LethF.Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.HIV Clin Trials2005; 6: 254–261.
32.
BognerJ.R.Nevirapine extended-release for the treatment of HIV-1 infection.Expert Rev Anti Infect Ther2012; 10: 21–30.
33.
GatheJ., BognerJ.R., SantiagoS.Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naive HIV-1 infected patients (VERxVE).XVIII International AIDS Conference. 18–23 July 2010, Vienna, Austria. Abstract THLBB202.
34.
HeilE.L., CorbettA.H.Guidelines for the use of extended-release nevirapine in HIV-infected patients.Expert Opin Pharmacother2011; 12: 2713–2718.
35.
StephanC., LeonW.Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy.HIV Med2014; 15: 124–128.
36.
TungarazaT.E., Talapan-ManikothP., JenkinsR.Curse of the ghost pills: the role of oral controlled-release formulations in the passage of empty intact shells in faeces. Two case reports and a literature review relevant to psychiatry.Therapeutic Advances in Drug Safety2013; 4: 63–71.
